Detailed Information

Cited 162 time in webofscience Cited 175 time in scopus
Metadata Downloads

Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart Disease Results of the CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) Trial

Authors
Suh, Jung-WonLee, Seung-PyoPark, Kyung-WooLee, Hae-YoungKang, Hyun-JaeKoo, Bon-KwonCho, Young-SeokYoun, Tae-JinChae, In-HoChoi, Dong-JuRha, Seung-WoonBae, Jang-HoKwon, Taek-GeunBae, Jang-WhanCho, Myeong-ChanKim, Hyo-Soo
Issue Date
Jan-2011
Publisher
ELSEVIER SCIENCE INC
Keywords
cilostazol; DES; platelet reactivity
Citation
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, v.57, no.3, pp 280 - 289
Pages
10
Indexed
SCI
SCIE
SCOPUS
Journal Title
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume
57
Number
3
Start Page
280
End Page
289
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/13774
DOI
10.1016/j.jacc.2010.08.631
ISSN
0735-1097
1558-3597
Abstract
Objectives We aimed to test whether cilostazol has beneficial effects in the real-world patients treated with intracoronary drug-eluting stents (DES). Background The addition of cilostazol on the conventional dual antiplatelet therapy has been reported to reduce platelet reactivity and to improve clinical outcomes after percutaneous coronary intervention in previous studies. Methods In a randomized multicenter trial, we enrolled 960 patients who received DES. They were randomized to receive either dual antiplatelet therapy (DAT) (aspirin and clopidogrel) or triple antiplatelet therapy (TAT) (aspirin, clopidogrel, and cilostazol) for 6 months. Primary end point was the composite of cardiac death, nonfatal myocardial infarction, ischemic stroke, or target lesion revascularization (TLR). Secondary end points were P2Y(12) reaction unit (PRU) measured with the VerifyNow P2Y12 assay (Accumetrics, San Diego, California) at discharge and at 6 months after the index procedure. All-cause death, stent thrombosis, and each component of the primary end point at 6 months were other secondary end points. Analysis was done on an intention-to-treat basis. Results At 6 months' follow-up, there was no difference in the primary end point between the 2 groups (8.5% in TAT vs. 9.2% in DAT, p = 0.74). In secondary end point analysis, the TAT group achieved lower PRU levels than the DAT group both at discharge (206.6 +/- 90.3 PRU vs. 232.2 +/- 80.3 PRU, p < 0.001) and at 6 months (210.7 +/- 87.9 PRU vs. 255.7 +/- 73.7 PRU, p < 0.001). In the Cox proportional hazards analysis, lesion length (>= 28 mm, hazard ratio [HR]: 2.10, 95% confidence interval [CI]: 1.25 to 3.52), and PRU level at discharge (every increase in tertile, HR: 1.61, 95% CI: 1.16 to 2.25) were predictors of the primary end point, but not the use of cilostazol (HR: 0.90, 95% CI: 0.54 to 1.52). Conclusions Despite the greater reduction of platelet reactivity by addition of cilostazol to conventional DAT, TAT did not show superiority in reducing the composite of adverse cardiovascular outcomes after DES implantation. (The Efficacy of CILostazol ON Ischemic Complications After DES Implantation [CILON-T]; NCT00776828) (J Am Coll Cardiol 2011;57:280-9) (C) 2011 by the American College of Cardiology Foundation
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Cardiology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Rha, Seung Woon photo

Rha, Seung Woon
Guro Hospital (Department of Cardiology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE